每经头条（nbdtoutiao）——实施城乡居民增收计划、降准降息等工具灵活高效运用、增加普通高中学 位……深度解读中央经济工作会议 （记者 曾健辉） 截至发稿，睿智医药市值为49亿元。 每经AI快讯，睿智医药（SZ 300149，收盘价：9.82元）12月12日晚间发布公告称，睿智医药科技股份 有限公司董事会秘书高莹莹女士因工作职务调整，申请辞去公司董事会秘书职务。 2025年1至6月份，睿智医药的营业收入构成为：医药研发服务及生产外包占比99.06%，益生元系列占 比0.52%，租金收入占比0.35%，其他行业占比0.07%。 ...

Company Overview - Ruizhi Pharmaceutical (SZ 300149) announced that on November 13, 2025, it will accept investor research led by Guoxin Securities, with CFO Cha Yinqun addressing investor questions [1] - As of the report, Ruizhi Pharmaceutical has a market capitalization of 5.8 billion yuan [1] Revenue Composition - For the first half of 2025, the revenue composition of Ruizhi Pharmaceutical is as follows: - Pharmaceutical research and development services and production outsourcing accounted for 99.06% - Prebiotic series accounted for 0.52% - Rental income accounted for 0.35% - Other industries accounted for 0.07% [1]

Group 1 - The core point of the article is that Ruizhi Pharmaceutical (SZ 300149) held its sixth board meeting on August 28, 2025, to review the semi-annual report and related documents [1] - For the fiscal year 2024, the revenue composition of Ruizhi Pharmaceutical is 99.03% from pharmaceutical research and development services and production outsourcing, while other businesses account for 0.97% [1] - As of the report, the market capitalization of Ruizhi Pharmaceutical is 6.2 billion yuan [1]